NRIX Jan 2025 20.000 call
- GlobeNewswire
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024. The event will be we
- Simply Wall St.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66%
Key Insights Significantly high institutional ownership implies Nurix Therapeutics' stock price is sensitive to their...
- Zacks
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
